<DOC>
	<DOCNO>NCT00637273</DOCNO>
	<brief_summary>This study compare benefit exenatide weekly treatment achieve approve antidiabetic therapy sitagliptin pioglitazone subject whose type 2 diabetes manage metformin therapy alone . The safety tolerability three treatment regimen also compare .</brief_summary>
	<brief_title>A Study Compare Glycemic Effects , Safety , Tolerability Exenatide Once Weekly Those Sitagliptin Pioglitazone , Subjects With Type 2 Diabetes Treated With Metformin ( DURATION - 2 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>2,4-thiazolidinedione</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Has diagnose type 2 diabetes mellitus Has hemoglobinspecific A1c fraction ( HbA1c ) 7.1 % 11.0 % , inclusive , study start Has body mass index ( BMI ) 25 kg/m2 45 kg/m2 , inclusive , study start Has stable treatment regimen metformin minimum 2 month prior study start Either treat stable treatment regimen follow medication minimum 2 month prior study start : 1 . Hormone replacement therapy ( female subject ) 2 . Oral contraceptive ( female subject ) 3 . Antihypertensive agent 4 . Lipidlowering agent 5 . Thyroid replacement therapy 6 . Antidepressant agent 7 . Drugs know affect body weight , include prescription medication ( e.g . orlistat [ XENICAL® ] , sibutramine [ MERIDIA® ] , topiramate [ TOPAMAX® ] ) overthecounter antiobesity agent Has previously expose exenatide weekly Has donate blood within 60 day study start plan donate blood study Currently treat , expect require undergo treatment follow treatmentexcluded medication : 1 . Exenatide ( BYETTA® ) Dipeptidyl peptidase4 DPP4 ) inhibitor , sulfonylurea ( SU ) , thiazolidinedione ( TZD ) , glucagonlike peptide ( GLP ) 1 analog within 3 month prior study start 2 . Alphaglucosidase inhibitor , meglitinide , nateglinide , pramlintide ( SYMLIN® ) within 30 day study start 3 . Insulin within 2 week study start 1 week within 3 month study start 4 . Systemic corticosteroid oral , intravenous , intramuscular route ; potent , inhale , intrapulmonary ( include ADVAIR® ) steroid know high rate systemic absorption 5 . Drugs interact CYP2C8 enzyme system , include gemfibrozil ( LOPID® ) rifampin Has receive investigational drug within 1 month ( five halflives investigational drug , whichever great ) study start Has previously experience clinically significant adverse event ( e.g. , significant edema ) relate TZD DPP4 inhibitor use</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>diabetes</keyword>
	<keyword>exenatide weekly</keyword>
	<keyword>Byetta</keyword>
	<keyword>sitagliptin</keyword>
	<keyword>Januvia</keyword>
	<keyword>thiazolidinedione</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
	<keyword>Pioglitazone</keyword>
</DOC>